JPS6242890B2 - - Google Patents

Info

Publication number
JPS6242890B2
JPS6242890B2 JP51123469A JP12346976A JPS6242890B2 JP S6242890 B2 JPS6242890 B2 JP S6242890B2 JP 51123469 A JP51123469 A JP 51123469A JP 12346976 A JP12346976 A JP 12346976A JP S6242890 B2 JPS6242890 B2 JP S6242890B2
Authority
JP
Japan
Prior art keywords
hepatitis
antigen
hours
immunizing antigen
vaccine according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP51123469A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5251019A (en
Inventor
Aaru Hiruman Moorisu
Jee Miraa Uiriamu
Jee Puroosuto Fuiritsupu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JPS5251019A publication Critical patent/JPS5251019A/ja
Publication of JPS6242890B2 publication Critical patent/JPS6242890B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP51123469A 1975-10-16 1976-10-16 Hepatisis a antigen Granted JPS5251019A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/623,184 US4017601A (en) 1975-10-16 1975-10-16 Hepatitis A antigen

Publications (2)

Publication Number Publication Date
JPS5251019A JPS5251019A (en) 1977-04-23
JPS6242890B2 true JPS6242890B2 (enExample) 1987-09-10

Family

ID=24497099

Family Applications (2)

Application Number Title Priority Date Filing Date
JP51123469A Granted JPS5251019A (en) 1975-10-16 1976-10-16 Hepatisis a antigen
JP62091857A Granted JPS62281822A (ja) 1975-10-16 1987-04-14 肝炎ａ抗原を得る方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP62091857A Granted JPS62281822A (ja) 1975-10-16 1987-04-14 肝炎ａ抗原を得る方法

Country Status (7)

Country Link
US (1) US4017601A (enExample)
JP (2) JPS5251019A (enExample)
BE (1) BE847343A (enExample)
DE (1) DE2646625A1 (enExample)
FR (1) FR2327999A1 (enExample)
GB (1) GB1526529A (enExample)
NL (1) NL188982C (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296024A (en) * 1974-12-09 1981-10-20 Merck & Co., Inc. Human immune serum globulin with high hepatitis A antibody titer
US4395395A (en) * 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
JPH0751513B2 (ja) * 1988-04-28 1995-06-05 国立予防衛生研究所長 Ａ型肝炎ワクチン
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
US6063038A (en) * 1999-04-09 2000-05-16 Clmp, Inc. Devices and methods for collecting fecal antigen specimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029764A (en) * 1974-12-09 1977-06-14 Merck & Co., Inc. Hepatitis A antigen

Also Published As

Publication number Publication date
NL188982C (nl) 1992-12-01
JPH0541609B2 (enExample) 1993-06-24
BE847343A (fr) 1977-04-15
US4017601A (en) 1977-04-12
GB1526529A (en) 1978-09-27
DE2646625A1 (de) 1977-04-28
DE2646625C2 (enExample) 1988-03-31
NL188982B (nl) 1992-07-01
FR2327999A1 (fr) 1977-05-13
JPS5251019A (en) 1977-04-23
JPS62281822A (ja) 1987-12-07
FR2327999B1 (enExample) 1981-11-27
NL7610657A (nl) 1977-04-19

Similar Documents

Publication Publication Date Title
Casals et al. The complement fixation test in the diagnosis of virus infections of the central nervous system
Svedmyr et al. Complement fixation with Brunhilde and Lansing poliomyelitis viruses propagated in tissue culture.
Thapar et al. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM)
CA1165237A (en) Particles of lipoid-soluble substances, compositions containing said particles and biologically active substances adsorbed thereon, and a process for the preparation thereof
CA1243954A (en) Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine
US4816253A (en) Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
JPH11513372A (ja) パラインフルエンザウイルスの糖タンパクおよびワクチン
US4567041A (en) Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
JPH11507805A (ja) 非細胞性百日咳ワクチンおよびその製造方法
CA1079634A (en) Antigens bound to exterior surface of microvesicles
JPS6242890B2 (enExample)
CN101450209A (zh) 透皮免疫流感多价疫苗的制备及其方法
US4029764A (en) Hepatitis A antigen
US5591771A (en) Use of propolis components as an adjuvant
JP3000569B2 (ja) Ｂ型肝炎ウイルスコア抗原のアミノ酸残基配列
Takahashi et al. Study on the Passive Hemagglutination Reaction by the Phosphatide of M. Tuberculosis: I. The Reaction and Its Specificity
Abusugra et al. ISCOM vaccine against contagious bovine pleuropneumonia (CBPP) 1. Biochemical and immunological characterization
US4031203A (en) Hepatitis A antigen
JP4053587B2 (ja) 不活性化レスピラトリーシンシシャルウイルスワクチン
Kramp et al. Liposomal enhancement of the immunogenicity of adenovirus type 5 hexon and fiber vaccines
RU2405568C2 (ru) Иммуногенная композиция
Viac et al. Specific immunity to human papilloma virus (HPV) in patients with genital warts.
Norrby et al. Humoral immunity to canine distemper after immunization of dogs with inactivated and live measles virus
Boutennoune et al. Induction of T helper 1 response by immunization of BALB/c mice with the gene encoding the second subunit of Echinococcus granulosus antigen B (EgAgB8/2)
US2720484A (en) Process for separation of viral substances from animal tissues